Nyrada Inc – Collaboration with World-class Teams at Walter Reed & UNSW Extended to 2025
• Collaboration with the Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney (UNSW) extended from February 2023 through… Read more
Nyrada Inc – Brain Injury Program Update
• In vitro safety and toxicology studies commenced 2H CY2022 and are tracking well • No change to start of… Read more
Nyrada Inc (ASX:NYR) Receives A$1.2M R&D Tax Incentive Rebate
Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and… Read more
Nyrada Inc – CEO Remuneration Update
Sydney, 27 October 2022: Nyrada Inc (ASX: NYR) (“Nyrada” or “the Company”) a preclinical stage, drug development company specialising in… Read more
Nyrada Quarterly Activities Report & Appendix 4C
Nyrada Inc. released its September quarterly report this morning – ASX release attached. The most significant point which Canary would… Read more
Nyrada Inc – 2022 AGM Letter to Shareholders and Proxy
Sydney, 18 October 2022: Nyrada Inc (ASX: NYR) (“Nyrada” or “the Company”) a preclinical stage, drug development company specialising in… Read more
NYX-PCSK9i Efficacy Study Published in Journal of Lipid Research
Nyrada Inc. (ASX: NYR) has had its NYX-PCSK9i Efficacy Study Published in Journal of Lipid Research, a highly regarded publication… Read more
Presentation to ShareCafe Hidden Gems Webinar
Nyrada Inc (ASX: NYR) is pleased to provide investors with the attached presentation, which will be given by Nyrada CEO,… Read more
NYRADA – Presentation to E&P Small Caps Health Care Conference
Nyrada Inc (ASX: NYR) is pleased to provide shareholders and the market generally with the attached presentation that will be… Read more